Counterpoint: Should antipyretic therapy be given routinely to febrile patients in septic shock? no

Anne M. Drewry; Richard S. Hotchkiss

doi:10.1378/chest.13-0918

Counterpoint: Should antipyretic therapy be given routinely to febrile patients in septic shock? no

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1098-1101
Number of pages	4
Journal	CHEST
Volume	144
Issue number	4
DOIs	https://doi.org/10.1378/chest.13-0918
State	Published - Oct 2013

Access to Document

10.1378/chest.13-0918

Cite this

@article{889de0b42fe845609cd4f784b6a58583,

title = "Counterpoint: Should antipyretic therapy be given routinely to febrile patients in septic shock? no",

author = "Drewry, \{Anne M.\} and Hotchkiss, \{Richard S.\}",

note = "Funding Information: Funding/Support: Dr Drewry receives support from the Washington University Institute of Clinical and Translational Sciences [Grant UL1TR000448] from the National Center for Advancing Translational Sciences. Dr Hotchkiss receives support from the National Institutes of Health [Grants GM44118 and GM55194]. Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Hotchkiss received grant support from MedImmune, LLC; Bristol-Myers Squibb; and Aurigene Discovery Technologies. Dr Drewry has reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. ",

year = "2013",

month = oct,

doi = "10.1378/chest.13-0918",

language = "English",

volume = "144",

pages = "1098--1101",

journal = "CHEST",

issn = "0012-3692",

number = "4",

}

TY - JOUR

T1 - Counterpoint

T2 - Should antipyretic therapy be given routinely to febrile patients in septic shock? no

AU - Drewry, Anne M.

AU - Hotchkiss, Richard S.

N1 - Funding Information: Funding/Support: Dr Drewry receives support from the Washington University Institute of Clinical and Translational Sciences [Grant UL1TR000448] from the National Center for Advancing Translational Sciences. Dr Hotchkiss receives support from the National Institutes of Health [Grants GM44118 and GM55194]. Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Hotchkiss received grant support from MedImmune, LLC; Bristol-Myers Squibb; and Aurigene Discovery Technologies. Dr Drewry has reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

PY - 2013/10

Y1 - 2013/10

UR - https://www.scopus.com/pages/publications/84885095403

U2 - 10.1378/chest.13-0918

DO - 10.1378/chest.13-0918

M3 - Editorial

C2 - 24081340

AN - SCOPUS:84885095403

SN - 0012-3692

VL - 144

SP - 1098

EP - 1101

JO - CHEST

JF - CHEST

IS - 4

ER -

Counterpoint: Should antipyretic therapy be given routinely to febrile patients in septic shock? no

Access to Document

Other files and links

Cite this